Physician profile
Joseph Lebowicz
NPI 1376543959
$3,919.64
in general payments reported to CMS, 2019-2025
50 companies · $716 in 2025
The $716 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $717 · 2021: $741 · 2022: $392 · 2023: $157 · 2024: $409 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.02 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $380.83 | 2019-2023 | |
| Janssen Biotech, INC. | $324.22 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Amgen INC. | $299.47 | 2019-2021 | |
| Glaxosmithkline, LLC. | $158.47 | 2022-2025 | Ojjaara |
| Astellas Pharma US INC | $152.35 | 2020-2024 | Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $139.77 | 2019-2025 | Ninlaro |
| Merck Sharp & Dohme LLC | $131.38 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Pfizer INC. | $129.27 | 2019-2025 | |
| Octapharma USA, INC. | $128.63 | 2020 | |
| Celgene Corporation | $120.89 | 2021-2022 | |
| Genzyme Corporation | $111.73 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $106.89 | 2020-2025 | Calquence |
| Seagen INC. | $106.64 | 2020-2022 | |
| Sobi, INC | $99.99 | 2025 | |
| Daiichi Sankyo INC. | $82.48 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lebowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.